News of meaningful new kidney treatments is always welcome. A couple of weeks ago, Scientific American published a special report exploring the wave of advances that are beginning to transform kidney care. The overview, by science writer Lauren Gravitz, brings together several areas where research is making genuine progress, from new drugs emerging from unexpected directions to smarter early warning systems for clinical teams.
What do these new kidney treatments involve?
One of the most significant themes in the report concerns medicines originally developed for other conditions entirely. As Scientific American explains, drugs created to treat diabetes and cardiovascular disease have shown meaningful protective benefits for the kidneys. Because kidney health, heart health, and metabolic conditions are so closely intertwined, researchers examining these existing medicines have uncovered important new kidney treatment possibilities that are already reaching some patients.
The publication also describes advances in IgA nephropathy, an autoimmune condition in which the immune system attacks the kidneys. Previously, people with this diagnosis had very few treatment options available to them. New medications are now giving clinicians tools to help patients who previously had almost nowhere to turn, and the report notes that earlier diagnosis will become increasingly important as these options expand.
A further development highlighted in the piece concerns alert systems designed to identify hospital patients most at risk of kidney damage from other medications they are receiving. The report describes how these systems can flag vulnerable individuals before permanent harm occurs, enabling care teams to reassess treatment in time.
You can read the full original report from Scientific American here: New drugs and treatments transform kidney care.
Why new kidney treatments matter for patients across the UK
For kidney patients in the UK, including those receiving care at Manchester Royal Infirmary, developments like these represent a genuine shift in what it is possible to hope for. One of the report’s most striking observations is that CKD remains significantly underdiagnosed, with a large proportion of those affected still unaware of their condition. Earlier detection combined with a broader range of new kidney treatments could make a real difference to how the condition is managed before it progresses.
For those already navigating kidney failure, knowing that the field of treatment is advancing from several directions at once matters enormously.
At MRIKPA, we take real encouragement when we see research pointing to improvements in the lives of people living with kidney disease. The fact that new kidney treatments are emerging from work done on diabetes and autoimmune conditions shows that progress in this area is gathering pace in ways nobody predicted, and that gives our community genuine grounds for hope.
— Guy Hill, Chair of MRIKPA
How soon could these advances become available through the NHS?
It is important to be clear that not all of the new kidney treatments described in the report will be immediately accessible through the NHS. Access depends on regulatory approvals, NICE recommendations, and individual clinical circumstances. If you are wondering whether any of these developments might be relevant to your own care, the best starting point is a conversation with your renal team, who will be best placed to advise on what is currently available to you.
At MRIKPA, we will continue to follow these developments and share updates as they emerge. If you would like to explore more about kidney health and the options available to patients, our Patient Knowledge Bank is a good place to begin, and you can stay up to date with the latest research on our Research and News page.
If you would like to connect with others who understand what it is like to live with kidney disease, our volunteers are always happy to hear from you. Contact us at support@mrikpa.org.uk or call 07745 242 684.
Source: Scientific American, March 2026 – read the original article
This article is provided for general information and awareness purposes only and was believed to be accurate at the time of publishing. It is not intended as medical advice — please always consult your doctor or renal team for guidance on your individual circumstances. Images used are for illustration purposes only and may not be medically or editorially accurate. While we take every care, errors can occur. If you spot an inaccuracy, please let us know at support@mrikpa.org.uk.
